N
RARE icon

Nuveen’s Ultragenyx Pharmaceutical RARE Stock Holding History

Nuveen’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.9M Sell
662,054
-139,419
-17% -$3.14M ﹤0.01% 1361
2025
Q4 		$18.4M Buy
801,473
+119,329
+17% +$3.92M ﹤0.01% 1193
2025
Q3 		$20.5M Buy
682,144
+176,992
+35% +$5.31M 0.01% 1130
2025
Q2 		$18.4M Sell
505,152
-13,391
-3% -$483K 0.01% 1155
2025
Q1 		$18.8M Buy
518,543
+129,882
+33% +$5.4M 0.01% 1161
2024
Q4 		$16.4M Sell
388,661
-4,099
-1% -$203K ﹤0.01% 1300
2024
Q3 		$21.8M Buy
392,760
+188,537
+92% +$9.6M 0.01% 1135
2024
Q2 		$8.39M Sell
204,223
-159,144
-44% -$6.8M ﹤0.01% 1689
2024
Q1 		$17M Sell
363,367
-94,080
-21% -$4.44M 0.01% 1277
2023
Q4 		$21.9M Buy
457,447
+26,775
+6% +$1.04M 0.01% 1093
2023
Q3 		$15.4M Sell
430,672
-1,018
-0.2% -$40.3K 0.01% 1205
2023
Q2 		$19.9M Sell
431,690
-19,728
-4% -$915K 0.01% 1066
2023
Q1 		$18.1M Sell
451,418
-12,951
-3% -$556K 0.01% 1110
2022
Q4 		$21.5M Buy
464,369
+260,212
+127% +$10.2M 0.01% 990
2022
Q3 		$8.45M Buy
204,157
+3,874
+2% +$199K ﹤0.01% 1587
2022
Q2 		$11.9M Sell
200,283
-57,862
-22% -$3.56M ﹤0.01% 1397
2022
Q1 		$17.8M Buy
258,145
+1,690
+0.7% +$118K 0.01% 1261
2021
Q4 		$21.6M Sell
256,455
-44,070
-15% -$3.59M 0.01% 1187
2021
Q3 		$27.1M Buy
300,525
+13,568
+5% +$1.23M 0.01% 1060
2021
Q2 		$27.4M Sell
286,957
-82,675
-22% -$8.61M 0.01% 1132
2021
Q1 		$42.1M Sell
369,632
-28,791
-7% -$3.92M 0.01% 813
2020
Q4 		$55.2M Buy
398,423
+14,017
+4% +$1.66M 0.02% 647
2020
Q3 		$31.6M Sell
384,406
-50,157
-12% -$4.16M 0.01% 798
2020
Q2 		$34M Buy
434,563
+103,472
+31% +$6.85M 0.01% 723
2020
Q1 		$14.7M Buy
331,091
+28,322
+9% +$1.47M 0.01% 1066
2019
Q4 		$12.9M Buy
302,769
+29,383
+11% +$1.21M ﹤0.01% 1435
2019
Q3 		$11.7M Sell
273,386
-1,695
-0.6% -$92.1K ﹤0.01% 1466
2019
Q2 		$17.5M Buy
275,081
+270,742
+6,240% +$17.2M 0.01% 1237
2019
Q1 		$301K Buy
+4,339
New +$248K ﹤0.01% 933
2017
Q3 		– Sell
-19,439
Closed -$1.21M – 1149
2017
Q2 		$1.21M Buy
19,439
+8,090
+71% +$487K 0.01% 712
2017
Q1 		$769K Sell
11,349
-3,368
-23% -$257K ﹤0.01% 1050
2016
Q4 		$1.03M Sell
14,717
-6,066
-29% -$430K 0.01% 1139
2016
Q3 		$1.47M Sell
20,783
-1,896
-8% -$121K 0.01% 914
2016
Q2 		$1.11M Buy
22,679
+5,331
+31% +$345K 0.01% 995
2016
Q1 		$1.1K Sell
17,348
-3,233
-16% -$212K 0.01% 989
2015
Q4 		$2.31K Sell
20,581
-1,133
-5% -$113K 0.01% 716
2015
Q3 		$2.09K Buy
21,714
+554
+3% +$63.4K 0.01% 745
2015
Q2 		$2.17K Buy
+21,160
New +$1.64M 0.01% 792

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Nuveen's RARE Position: Q1 2026 in Review

Nuveen reduced its Ultragenyx Pharmaceutical (RARE) stake by 17% in Q1 2026, selling an estimated $3.14M and leaving 662,054 shares worth $13.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1361.

Nuveen first reported a position in RARE in Q2 2015 and has held it in 38 quarters since. The position peaked at $55.2M in Q4 2020. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Nuveen held 662,054 shares of Ultragenyx Pharmaceutical worth $13.9M as of Q1 2026.
  • Nuveen sold 139,419 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $3.14M.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #1361 holding.
  • Nuveen first reported a position in Ultragenyx Pharmaceutical in Q2 2015 and has held it in 38 quarters since.
  • Nuveen's Ultragenyx Pharmaceutical position peaked at $55.2M in Q4 2020.
  • 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.